MX354215B - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents
Inhibidores de la proteina 90 de choque termico (hsp90).Info
- Publication number
- MX354215B MX354215B MX2013011531A MX2013011531A MX354215B MX 354215 B MX354215 B MX 354215B MX 2013011531 A MX2013011531 A MX 2013011531A MX 2013011531 A MX2013011531 A MX 2013011531A MX 354215 B MX354215 B MX 354215B
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- pharmaceutically acceptable
- independently
- compound
- effective amount
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| PCT/US2012/032373 WO2012138896A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011531A MX2013011531A (es) | 2014-08-22 |
| MX354215B true MX354215B (es) | 2018-02-19 |
Family
ID=46018086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011531A MX354215B (es) | 2011-04-05 | 2012-04-05 | Inhibidores de la proteina 90 de choque termico (hsp90). |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9546170B2 (enExample) |
| EP (1) | EP2694506B1 (enExample) |
| JP (1) | JP5961683B2 (enExample) |
| KR (1) | KR101984480B1 (enExample) |
| CN (1) | CN103596955B (enExample) |
| AU (1) | AU2012240079B2 (enExample) |
| BR (1) | BR112013025761A2 (enExample) |
| CA (1) | CA2832099C (enExample) |
| EA (1) | EA024647B1 (enExample) |
| ES (1) | ES2647889T3 (enExample) |
| MX (1) | MX354215B (enExample) |
| WO (1) | WO2012138896A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| ES2624982T3 (es) | 2011-07-08 | 2017-07-18 | Sloan-Kettering Institute For Cancer Research | Usos de inhibidores etiquetados HSP90 |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| JP7132848B2 (ja) | 2015-10-05 | 2022-09-07 | メモリアル スローン ケタリング キャンサー センター | 癌の治療のための合理的併用療法 |
| MX2025007723A (es) | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| JP2026509913A (ja) * | 2023-03-17 | 2026-03-25 | アトモスアール | Ｈｓｐ９０阻害剤としてのアデニン誘導体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE460423T1 (de) | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| NZ535592A (en) | 2002-02-28 | 2006-07-28 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
| US7592143B2 (en) | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ZA200801822B (en) | 2005-08-26 | 2009-09-30 | Serono Lab | Pyrazine derivatives and use as p13k inhibitors |
| WO2007075572A2 (en) | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| AU2007249194B2 (en) | 2006-05-12 | 2012-11-22 | Myrexis, Inc. | Therapeutic compounds and their use in cancer |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| WO2008115262A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| EP2183221A1 (en) | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| AU2008322503A1 (en) | 2007-11-14 | 2009-05-22 | Myrexis, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| CA3017874A1 (en) | 2009-01-16 | 2010-07-22 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
-
2012
- 2012-04-05 MX MX2013011531A patent/MX354215B/es active IP Right Grant
- 2012-04-05 ES ES12717521.4T patent/ES2647889T3/es active Active
- 2012-04-05 JP JP2014503996A patent/JP5961683B2/ja not_active Expired - Fee Related
- 2012-04-05 US US14/110,095 patent/US9546170B2/en active Active
- 2012-04-05 CN CN201280027360.XA patent/CN103596955B/zh not_active Expired - Fee Related
- 2012-04-05 KR KR1020137029258A patent/KR101984480B1/ko not_active Expired - Fee Related
- 2012-04-05 AU AU2012240079A patent/AU2012240079B2/en not_active Ceased
- 2012-04-05 WO PCT/US2012/032373 patent/WO2012138896A1/en not_active Ceased
- 2012-04-05 BR BR112013025761A patent/BR112013025761A2/pt not_active IP Right Cessation
- 2012-04-05 EA EA201391337A patent/EA024647B1/ru not_active IP Right Cessation
- 2012-04-05 EP EP12717521.4A patent/EP2694506B1/en active Active
- 2012-04-05 CA CA2832099A patent/CA2832099C/en active Active
-
2016
- 2016-12-09 US US15/374,007 patent/US10064867B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391337A1 (ru) | 2014-05-30 |
| US10064867B2 (en) | 2018-09-04 |
| US20140045867A1 (en) | 2014-02-13 |
| NZ616890A (en) | 2016-01-29 |
| KR101984480B1 (ko) | 2019-05-31 |
| KR20140073464A (ko) | 2014-06-16 |
| JP2014510149A (ja) | 2014-04-24 |
| EA024647B1 (ru) | 2016-10-31 |
| EP2694506B1 (en) | 2017-09-20 |
| CA2832099C (en) | 2019-07-09 |
| BR112013025761A2 (pt) | 2018-05-29 |
| MX2013011531A (es) | 2014-08-22 |
| WO2012138896A1 (en) | 2012-10-11 |
| AU2012240079B2 (en) | 2017-05-18 |
| CN103596955B (zh) | 2016-11-16 |
| JP5961683B2 (ja) | 2016-08-02 |
| CA2832099A1 (en) | 2012-10-11 |
| US9546170B2 (en) | 2017-01-17 |
| AU2012240079A1 (en) | 2013-11-07 |
| EP2694506A1 (en) | 2014-02-12 |
| ES2647889T3 (es) | 2017-12-27 |
| US20170151247A1 (en) | 2017-06-01 |
| CN103596955A (zh) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013011531A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| MX360390B (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| NZ603155A (en) | Phospholipid drug analogs | |
| JP2014510149A5 (enExample) | ||
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| CR20140301A (es) | Derivados de betulina | |
| TN2015000121A1 (en) | Gdf-8 inhibitors | |
| PH12015502675A1 (en) | Cycloaklane derivative | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| TN2012000401A1 (en) | Heterocyclic compound | |
| PH12016501048A1 (en) | Piperidine derivatives as mdm2 inhibitors for the treatment of cancer | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| MY172924A (en) | Neprilysin inhibitors | |
| WO2014078295A8 (en) | Gemcitabine prodrugs and uses thereof | |
| MX2013005508A (es) | Compuestos de lipoilo y su uso para tratar lesion isquemica. | |
| NZ712660A (en) | Dicarboxylic acid compound | |
| PH12016500838A1 (en) | Isoxazolines as therapeutic agents | |
| IN2014CN04449A (enExample) | ||
| MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |